Semaglutide and Tirzepatide Use and Reduction of Cardiovascular Risks in Adults with Overweight and Obesity
Main Article Content
Abstract
Background: Obesity is a prevalent, growing health concern in the United States, affecting over 42% of adults and contributing significantly to the burden of cardiovascular disease (CVD). Recently, approved anti-obesity medications (AOMs) such as semaglutide (Wegovy) and tirzepatide (Zepbound) have emerged as potential interventions to reduce weight and potentially lower cardiovascular risk among individuals with obesity.
Aim: To analyze the impact of AOM on cardiovascular risk among US patients with obesity.
Methods: Utilizing Kythera data, we conducted a retrospective cohort study from November 2022 to June 2024. Patients with obesity and AOM use were identified based on diagnosis claims and prescription claims for tirzepatide or semaglutide (identification period: Nov. 1, 2023–Dec. 31, 2023) with 6 months of follow-up to measure CVD risk. Exclusions included patients with pre-existing CVD and prior AOM use. Cox regression and multivariable analyses adjusted for comorbidities and sociodemographic factors were employed to assess the risk of cardiovascular events, with additional analyses comparing outcomes between tirzepatide and semaglutide users.
Results: We identified 22,620 patients with obesity and AOM use and 84,427 patients with obesity without AOM use. Significant differences were observed in the proportion of patients with an Elixhauser Index Score ≥2, comprising 61.97% in the AOM cohort versus 13.50% in the non-AOM cohort (standardized difference = 1.2868). The AOM cohort demonstrated significantly lower incidence of cardiovascular events (1.77%) than non-AOM users (12.17%, p<0.0001). Adjusted analyses confirmed that AOM use was associated with a substantially reduced risk of CVD (hazard ratio=0.37, p<0.0001). Differences in specific cardiovascular outcomes between tirzepatide and semaglutide users were observed, with semaglutide users showing a higher hazard of CVD than tirzepatide users (hazard ratio=1.53, p=0.0215).
Conclusions: Use of AOM was associated with a significantly lower risk-adjusted likelihood of cardiovascular events than non-use, highlighting these medications as promising interventions in obesity management.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984-e1010.
3. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113(6):898-918.
4. Lichtenstein AH, Appel LJ, Vadiveloo M, et al. 2021 dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2021;144(23):e472-e487.
5. Kajikawa M, Higashi Y. Obesity and endothelial function. Biomedicines. 2022;10(7):1745.
6. Engeli S, Sharma A. Role of adipose tissue for cardiovascular-renal regulation in health and disease. Hormone and Metabolic Research. 2000;32(11/12):485-499.
7. de Divitiis O, Fazio S, Petitto M, Maddalena G, Contaldo F, Mancini M. Obesity and cardiac function. Circulation. 1981;64(3):477-482.
8. De Sousa A, Cercato C, Mancini M, Halpern A. Obesity and obstructive sleep apnea‐hypopnea syndrome. Obesity Reviews. 2008;9(4):340-354.
9. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004;110(18):2952-2967.
10. Petrofsky J, Batt J. Weight loss and cardiovascular fitness during a 1-week diet and exercise program. diabetes. 2006;5:8.
11. Ross R, Janiszewski PM. Is weight loss the optimal target for obesity-related cardiovascular disease risk reduction? Canadian Journal of Cardiology. 2008;24:25D-31D.
12. Castro EA, Peinado AB, Benito PJ, et al. What is the most effective exercise protocol to improve cardiovascular fitness in overweight and obese subjects? Journal of sport and health science. 2017;6(4):454-461.
13. Fujioka K. Safety and tolerability of medications approved for chronic weight management. Obesity (19307381). 2015;23
14. Samaranayake NR, Ong KL, Leung RY, Cheung BM. Management of obesity in the national health and nutrition examination survey (NHANES), 2007–2008. Annals of epidemiology. 2012;22(5):349-353.
15. Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine. 2022;70(1):5-13.
16. Abbasi J. FDA green-lights tirzepatide, marketed as zepbound, for chronic weight management. JAMA. 2023;
17. Qin W, Yang J, Ni Y, et al. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. Endocrine. 2024:1-15.
18. Michos ED, Lopez‐Jimenez F, Gulati M. Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity. Journal of the American Heart Association. 2023;12(11):e029282.
19. Gilbert D, Ovalle D. FDA approves new obesity drug from Eli Lilly named Zepbound. The Washington Post. 2023:NA-NA.
20. Baser O, Samayoa G, Yapar N, Baser E, Mete F. Use of open claims vs closed claims in health outcomes research. Journal of Health Economics and Outcomes Research. 2023;10(2):44.
21. Baser O, Samayoa G, Rodchenko K, Isenman L, Baser E, Yapar N. The association between weight loss medications and cardiovascular complications. Obesity (Silver Spring). 2024;32(7):1401-1409.
22. Baser O, Isenman L, Baser S, Samayoa G. Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study. Obesity Science & Practice. 2024;10(3):e762.
23. Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of clinimetric properties. Psychotherapy and psychosomatics. 2022;91(1):8-35.
24. Scheike TH, Zhang M-J. Extensions and applications of the Cox-Aalen survival model. Biometrics. 2003;59(4):1036-1045.
25. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:1-20.
26. Caleyachetty R, Thomas GN, Toulis KA, et al. Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. Journal of the American College of Cardiology. 2017;70(12):1429-1437.
27. Yurkow S, Ivezaj V, Grilo CM. Improvements in cardiovascular disease risk factors associated with modest weight loss following treatment in patients with binge‐eating disorder and obesity. International Journal of Eating Disorders. 2023;56(11):2074-2083.
28. Collaboration PS. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-1096.
29. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine. 2023;389(12):1069-1084.
30. Kosiborod MN, Verma S, Borlaug BA, et al. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation. 2024;149(3):204-216.
31. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023;389(24):2221-2232.
32. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009;119(18):2516-2525.
33. Minhas AMK, Jain V, Li M, et al. Family income and cardiovascular disease risk in American adults. Scientific Reports. 2023/01/06 2023;13(1):279. doi:10.1038/s41598-023-27474-x
34. Gallucci G, Tartarone A, Lerose R, Lalinga AV, Capobianco AM. Cardiovascular risk of smoking and benefits of smoking cessation. Journal of Thoracic Disease. 2020;12(7):3866.
35. Major RW, Cheng MR, Grant RA, et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PloS One. 2018;13(3):e0192895.
36. Alloubani A, Nimer R, Samara R. Relationship between hyperlipidemia, cardiovascular disease and stroke: a systematic review. Current Cardiology Reviews. 2021;17(6)
37. Clebak KT, Dambro AB. Hyperlipidemia: an evidence-based review of current guidelines. Cureus. 2020;12(3)
38. Laranjo L, Lanas F, Sun MC, et al. World Heart Federation roadmap for secondary prevention of cardiovascular disease: 2023 update. Global Heart. 2024;19(1)
39. Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular risks associated with gender and aging. Journal of Cardiovascular Development and Disease. 2019;6(2):19.
40. Sanz M, Marco del Castillo A, Jepsen S, et al. Periodontitis and cardiovascular diseases: Consensus report. Journal of Clinical Periodontology. 2020;47(3):268-288.
41. Ismaiel A, Dumitraşcu DL. Cardiovascular risk in fatty liver disease: the liver-heart axis—literature review. Frontiers in Medicine. 2019;6:202.
42. Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. Journal of Health Economics. 2012;31(1):219-230.
43. Tchang BG, Aras M, Kumar RB, Aronne LJ. Pharmacologic Treatment of Overweight and Obesity in Adults. In: Feingold KR, Anawalt B, Blackman MR, et al, eds. Endotext. MDText.com, Inc.; 2000.
44. Birger M, Kaldjian AS, Roth GA, Moran AE, Dieleman JL, Bellows BK. Spending on cardiovascular disease and cardiovascular risk factors in the United States: 1996 to 2016. Circulation. 2021;144(4):271-282.